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Abstract
·AIM: To evaluate outcomes of combined pars plana
vitrectomy and Baerveldt glaucoma implant (PPV -BGI)
placement for refractory glaucoma.
· METHODS: The medical records of 92 eyes (89
patients) that underwent PPV -BGI were retrospectively
reviewed, including 43 eyes with neovascular glaucoma
(NVG) and 49 eyes with other types of glaucoma (non-
NVG).
·RESULTS: Outcome measures were visual acuity (VA),
intraocular pressure (IOP), glaucoma medical therapy,
complications, and success [VA >hand motions (HM),
IOP 逸6 mm Hg and 臆21 mm Hg, no subsequent
glaucoma surgery]. Cumulative success rates for the
non -NVG group and NVG group were 79% and 40% at
1y, respectively ( =0.038). No difference in the rates of
surgical success were found between pars plana and
anterior chamber tube placement. Preoperative IOP
(mean依SD) was 30.3依11.7 mm Hg in the Non-NVG group
and 40.0依10.6 mm Hg in the NVG group, and IOP was
reduced to 15依9.5 mm Hg in the non-NVG group and 15依
10.5 mm Hg in the NVG at 1y. Number of glaucoma
medications (mean依SD) decreased from 2.7依1.3 in the
non -NVG group and 2.8 依1.3 in the NVG group
preoperatively to 0.76依1.18 in the non -NVG group and
0.51依1.00 in the NVG group at 1y. Improvement in VA of
逸2 Snellen lines was observed in 25 (27% ) eyes,
although only 33% of non -NVG eyes and 2.3% of NVG
eyes maintained VA better than 20/200 at 1y. Nonclearing
vitreous hemorrhage was the most common
postoperative complication occurring in 16 (17%) eyes,
and postoperative suprachoroidal hemorrhages
developed in 5 (5.4%) eyes.
·CONCLUSION: PPV-BGI is a viable surgical option for
eyes with refractory glaucoma, but visual outcomes are
frequently poor because of ocular comorbidities,
especially in eyes with NVG. The location of tube
placement does not influence surgical outcome and
should be left to the discretion of the surgeon.
· KEYWORDS: glaucoma drainage device; pars plana
vitrectomy; refractory glaucoma; neovascular glaucoma
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INTRODUCTION
G laucoma drainage devices (GDDs) have traditionallybeen used in eyes at high risk for trabeculectomy
failure, such as those with pediatric glaucoma, uveitic
glaucoma, secondary glaucoma after penetrating keratoplasty,
and neovascular glaucoma (NVG) [1-8]. The GDD tube is
usually inserted into the anterior chamber (AC), but it may be
placed through the pars plana into the vitreous cavity if
corneal endothelial decompensation or AC angle
abnormalities are present [3,5,9-20]. Pars plana vitrectomy (PPV)
is required to avoid vitreous occlusion of the tube ostium if
placed into the vitreous cavity. A vitrectomy may also be
required with tube insertion into the AC in the presence of
vitreous prolapse, as is commonly seen in aphakia eyes.
Glaucoma patients with coexisting posterior segment diseases
may be considered for combined PPV and GDD
implantation, such as patients with NVG who require both
panretinal laser photocoagulation (PRP) and intraocular
pressure (IOP) reduction [21-23]. Successful IOP reduction has
been reported with the combination of PPV with implantation
of various types of GDD's in case reports and small case
series in eyes with complex diseases [2,9-18]. Studies of
Baerveldt glaucoma implants (BGI) (Abbott Medical Optics,
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Santa Ana, California, USA) combined with PPV and
insertion into the vitreous cavity have not been widely
published [11,14,20]. The purpose of this study is to report the
outcomes of a large cohort of patients who underwent PPV
and BGI placement (PPV-BGI), and to compare the
outcomes between the NVG and non-NVG cases.
SUBJECTS AND METHODS
This study was approved by the Human Subjects Committee
of the University of Miami Miller School of Medicine, and
was conducted in accordance with the Declaration of
Helsinki for research in human subjects. The medical records
of all patients who underwent PPV-BGI at the Bascom
Palmer Eye Institute between January 1, 1992 and May 31,
2007 by one vitreoretinal surgeon (Smiddy WE) were
identified using Current Procedural Terminology (CPT)
codes and retrospectively reviewed. Implantation of a BGI
was performed by one of the other authors (Gedde SJ,
Budenz DL, Parrish RK 域 and Palmberg PF). Demographic
information, surgical indication, lens status, number of
previous intraocular surgeries, preoperative AC angle status,
presence of preoperative hyphema, presence of iris or angle
neovascularization, adjunctive procedures performed during
surgery, complications, pre- and post-operative best-corrected
visual acuity (BCVA) and IOP, number of antiglaucoma
medications, and post-operative interval until last follow-up
examination were extracted from the medical record.
The surgical procedure consisted of a three-port, 20-gauge
PPV performed in conjunction with the placement of a BGI
in the superotemporal quadrant. Temporary restriction of
aqueous flow through the implant was achieved with a tube
ligation with a 7-0 polyglactin suture near the tube-plate
junction. Fenestrations were created in the tube with a
TG-130 needle just anterior to the polyglactin ligature with a
needle for early IOP control according to the glaucoma
surgeon's judgment. The tube was placed through the pars
plana into the vitreous cavity either through a sclerotomy
created by the 20-gauge microvitreoretinal blade or through a
separate 23-gauge needle tract. It was the consensus of the
glaucoma specialist that the Hoffman elbow modification of
the BGI was not necessary and, hence, it was not used. A
donor corneal or scleral patch graft was applied over the
anterior portion of the tube to prevent erosion. Patients were
monitored post-operatively by both the glaucoma and
vitreoretinal surgeons.
Patients were categorized by diagnosis as NVG or non-NVG
for the purpose of data analysis. The main outcome measure
was success defined as BCVA逸hand motions (HM), normal
IOP (逸6 and 臆21 mm Hg) with or without antiglaucoma
medication, and no additional ocular surgery. Eyes that did
not fail but required adjunctive glaucoma medications were
classified as qualified successes, while those without
glaucoma medications were categorized as complete
successes. Hypotony was defined as IOP 臆5 mm Hg. Data
from the clinic visit nearest to 12mo post-operatively (range,
7 to 18mo) were analyzed for 1y outcomes.
SPSS (Version 17, SPSS Inc. Chicago, Il, USA) was used for
statistical analysis. Demographic data and preoperative data
between the NVG group and non-NVG group were analyzed
with a paired 2-sample test. IOP comparisons between two
groups were analyzed with a paired 2-sample -test. Rates of
surgical success, surgical failure, postoperative hypotony, and
visual acuity change were analyzed by Chi-square test. The
incidence of complications was analyzed with the Fisher
Exact test. Kaplan-Meier survival analysis was used to
calculate success rates.
RESULTS
Baseline Characteristics Table 1 shows the baseline
Table 1 Baseline characteristics of the study population 
Data analyzed  NVG Non-NVG P  
No. of eyes 43 49  
No. of patients 41 48  
Age (a)     
  Mean (SD)  65 (15) 62.51 (22.95) 0.55a 
  Median (range)  64 (36-92) 69 (5-90)  
Gender     
  Male, n (%) 23 (53) 22 (45) 0.34b 
Follow-up (mo)     
  Mean (SD)  16 (15) 23 (21) 0.031a 
  Median (range)  11 (1-84) 15 (1-84)  
Lens status, n (%)    0.02c 
  Phakic  20 (47) 10 (20)  
  Aphakia 2 (5) 5 (10)  
  ACIOL  2 (5) 9 (18)  
  PCIOL  19 (44) 25 (51)  
VA, logMAR    
  Mean (SD)  2.23 (0.48) 1.51 (0.75) <0.001a 
  Median (range)  2.3 (0.7-3.0) 1.3 (0.18-3.0)  
IOP (mm Hg)     
  Mean (SD)  40.0 (10.6) 30.3 (11.7) <0.001a 
  Median (range)  39 (17-60) 31 (6-55)  
Extent of angle closure by 
PAS, n (%)    0.24
c 
  PAS (-) /open angle 13 (30) 15 (31)  
  <180 degrees  13 (30) 8 (16)  
  ≥180 degrees  17 (40) 26 (53)  
Antiglaucoma medications, 
n mean (SD) 2.8 (1.3) 2.7 (1.3) 0.56
a 
Mean number previous 
intraocular surgeries, n




1.8 (1.4) <0.001a 
ACIOL: Anterior chamber IOL; IOP: Intraocular pressure; 
logMAR: Logarithm of minimal angle resolution; NVG: 
Neovascular glaucoma; PAS: Peripheral anterior synechia; 
PCIOL: Posterior chamber lens; VA: Visual acuity. aTwo-sample 
t-test; bFisher Exact test; cPearson Chi-square test. 
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characteristics of the study population. Ninety two eyes from
89 patients were included in the study. The NVG group
consisted of 43 eyes from 41 patients, and proliferative
diabetic retinopathy (14 eyes, 33%) and central retinal vein
occlusion (4 eyes, 9%) were the most common underlying
etiologies. The non-NVG group consisted of 49 eyes of 48
patients, and the most common surgical indications were
prior penetrating keratoplasty (8 eyes, 16%) and aphakia with
vitreous prolapse (6 eyes, 12%). The median age (64y
69y), male gender (53% 45%), median follow-up interval
(11mo 15mo), rate of 逸50% angle closure (40%
53% ), and number of preoperative glaucoma medications
(2.8 2.7) were not significantly different between the
NVG group and non-NVG group, respectively. The
non-NVG group had better preoperative vision (median
logMAR 1.3 2.3, <0.001), lower median IOP (31 mm Hg
39 mm Hg, <0.001), and more previous intraocular
surgeries (mean 1.8 0.7, <0.001) in comparison to the
NVG group.
Preoperatively there were a total of 55 pseudophakic, 7
aphakic, and 30 phakic eyes. Cataract extraction was
performed during follow-up in the study in 8 (27%) phakic
eyes. The NVG group was more commonly phakic (47%)
than the non-NVG group (20%) at the time of BGI placement
( =0.023). Other ocular comorbidities included tractional
retinal detachment (2 eyes; one due to PDR and one due to
sickle cell retinopathy), retained lens material, aqueous
misdirection, traumatic glaucoma, and aniridia (one each).
Tube fenestrations were performed in 33 (67%) of non-NVG
and in 40 (93%) of NVG eyes.
Surgical Outcomes Surgical outcomes are provided in
Table 2. Surgical failure occurred in 34 (37%) of the 92 eyes
with at least 1y follow-up, including 26 (60%) of the NVG
group and 8 (16%) of the non-NVG group ( =0.038). Vision
loss to NLP (16 eyes, 23%), IOP <6 or >21 mm Hg (6 eyes,
18%), phthisis or enucleation (14 eyes, 41%) and glaucoma
reoperations (6 eyes, 18% ) were the causes for treatment
failure. Two eyes in the NLP category underwent enucleation
due to a blind, painful eye. The reoperations included PPV
due to vitreous hemorrhage (VH) or fibrovascular
proliferation (2 eyes), BGI revision (1 eye), BGI replacement
(2 eyes), and BGI removal (1 eye). Failure on treatment was
evident within 6mo post-operatively in 20 (59%) of the 34
eyes. The cumulative probability of success at 1y using
Kaplan-Meier survival analysis was worse in the NVG group
than in the non-NVG group (40% 79% ; <0.001), a
difference that persisted thereafter (Figure 1).
Tube Location The tube was placed into the AC in 48
(52%) eyes (including 20 pseudophakic, 4 aphakic, and 24
phakic eyes) and into the vitreous cavity in 44 (48%) eyes
(including 35 pseudophakic, 3 aphakic, and 6 phakic eyes).
The tube was more frequently placed into the AC in the NVG
group (81%) than in the non-NVG group (27%) ( <0.001),
and in phakic (80%) compared to aphakic or pseudophakic
(38%) eyes.
Mean IOP at one-year follow-up visit was 15 mm Hg for
both NVG and Non-NVG groups ( =0.425) and the mean
number of antiglaucoma medications was reduced from a
mean of 2.8 in the NVG group and 2.7 in the non-NVG
preoperatively to 0.51 and 0.76, respectively ( =0.343).
Paired -test for postoperative compared to preoperative.
Visual Results Visual results were better in the non-NVG
group (Table 2). After one-year follow-up, 16 (37%) of the
NVG eyes presented visual acuity ranging between HM and
Figure 1 Kaplan-Meier plot of cumulative proportion of eyes
failing visual acuity or intraocular pressure criteria for
successful outcome.
Table 2 Surgical outcomes 
Data analyzed NVG n=43 
Non-NVG 
n=49 P 
Tube location, n (%)    <0.001a
  AC 35 (81) 13 (27)  
  PP 8 (19) 36 (73)  
Visual Outcome at final 
visit, n (%)    0.007
a 
  Improved  10 (23) 27 (55)  
  Stable  13 (30) 10 (20)  
  Worse  20 (47) 12 (24)  







Mean IOP at 1a, mm Hg 
(SD) 15 (10.5) 15 (9.5) 0.425 
Treatment outcomes at final 
visit, n (%)   <0.001
a
  Complete success 8 (19) 26 (53)  
  Qualified success 9 (21) 15 (31)  
  Failure 26 (60) 8 (16)  
Mean number of glaucoma 
medications at 1a, n (SD) 0.51 (1.00) 0.76 (1.18) 0.343 
AC: Anterior chamber; IOP: Intraocular pressure; NLP: No light 
perception; NVG: Neovascular glaucoma; PP: Pars plana. a 
Analyzed by Pearson Chi-square test; bFisher Exact test. 
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counting fingers and only one eye (2% , VA = 20/70)
presented visual acuity 逸20/200, while 16 (33% ) of 42
non-NVG eyes achieved Snellen visual acuity 逸 20/200
( =0.001). Visual acuity was stable or improved in 75% of
non-NVG eyes ( 53% in the NVG group).
Complications Table 3 shows complications and associated
surgical procedures during the first year of follow-up. The
only intraoperative complication, a suprachoroidal
hemorrhage, occurred in a non-NVG patient after a
penetrating keratoplasty. Postoperative complications
occurred in 28 (65%) NVG and 24 (49%) non-NVG eyes.
The most common complications that were present at or
beyond 1wk post-operatively in NVG patients included
non-clearing VH and/or hyphema in 16 eyes (37% ). In
contrast, none of the non-NVG eyes had a VH by the first
post-operative week. The persistence of VH/hyphema likely
indicated continuing hemorrhage due to progressive
underlying disease. Postoperative VH was an important
prognostic factor in the NVG group; 88% of NVG patients
with non-clearing VH ultimately were surgical failures.
Postoperative suprachoroidal hemorrhage requiring surgical
drainage within 2wk post-operatively occurred in 5 (10% )
non-NVG eyes, two of which developed phthisis.
Suprachoroidal hemorrhage did not occur in any NVG cases.
Post-operative retinal detachment (3 cases in each group, 7%
of total) or retinal breaks without retinal detachment (1 eye in
the non-NVG group, 1% of total) also occurred (Tables 3, 4).
DISCUSSION
This study has demonstrated that PPV combined with GDD
can offer respectable results, considering it is a treatment
option for the most advanced cases, and specifically that eyes
with non-NVG have a better prognosis. Potential advantages
of this procedure in selected patients with uncontrolled IOP
includes simultaneous management of glaucoma and
posterior segment disorders and the option of pars plana
placement of the drainage tube for patients with anterior
segment comorbidities [12,14,16,20]. Previous studies of combined
procedures have been limited to small cases of various types
of GDD's[2,9-18], offered limited comparison outcomes of NVG
to other indications, used broader criteria for success (
inclusion of light perception final visual acuity as success), or
lacked details of visual acuity results [14,16,17,20]. The present
study included a large number of patients who underwent a
single type of GDD, and outcomes are subdivided into eyes
with NVG and those with other glaucoma diagnoses.
Glaucoma type was a major factor affecting surgical success
in this study, with NVG eyes fairing substantially worse than
non-NVG eyes. The Kaplan-Meier cumulative success one
year post-operatively (40% in NVG eyes and 79% in the
non-NVG eyes) in the current study was similar to previously
reported success rates of 43% to 78% for BGI which lumped
all glaucoma categories [24-26]. Our study design did not permit
a controlled evaluation of combined PPV/BGI in regards to
BGI placement only or placement by location, but a
reasonable inference from these data is that the tube site may
be effectively decided by the surgeon based upon constraints
in an individual eye. The more frequent pars plana placement
in non-NVG eyes (73% ) was probably due to associated
anterior segment pathology that was more chronic or
reflected previous surgical attention, such as vitreous
prolapse commensurate with aphakia and pseudophakia.
The poor visual outcome of NVG patients in the current
series is consistent with those reported previously, and is
likely attributable to their poorer baseline visual acuity and
natural history. A previous study reporting 56% success and
28% qualified success among 50 NVG eyes considered eyes
with LP visual acuity as successes, and did not offer a
detailed visual acuity analysis [20]. Still they acknowledged
"serious complications" in 10% of eyes, consistent with the
findings of the current study which offers a sober prognosis
among NVG eyes. A recent retrospective study evaluated the
Table 3 Complications and associated surgical procedures during 
1y follow-up 
Complications NVG n=43 
Non-NVG 
n=49 
Choroidal detachment 3 6 
Retinal breaks with RD 3 3 
Retinal breaks without RD 0 1 
Unclearing VHa 16 0 
Endophthalmitis 2 0 
Flat AC 1 0 
Tube blockage by vitreous 0 2 
IOL dislocation 0 3 
Exposed tube 0 1 
Corneal endothelial failure 2 4 
Enucleated 2 0 
Phthisis 12 2 
Repeated surgery 3 3 
Cataract progression 





VA LP or NLP 8 0 
IOP  <6  or  >21 mm Hg 3 3 
Total (number of eyes) 56 (28) 28 (24) 
IOL: Intraocular lens; IOP: Intraocular pressure; NLP: No light 
perception; NVG: Neovascular glaucoma; RD: Retinal detachment; 
SCH: Suprachoroidal hemorrhage; VH: Vitreous hemorrhage; VA: 
Visual acuity; LP: Light perception. aUnclearing VH: Vitreous 
hemorrhage not cleared till 1mo post-operatively. 
 
Table 4 Postoperative complications on first postoperative day 
Complications NVG n=43 
Non-NVG 
n=49 
Hypotony 3 13 
Hyphema 26 7 
VH 25 10 
SCH 0 5 
Total (number of eyes) 54 (26) 35 (20) 
SCH: Suprachoroidal hemorrhage; VH: Vitreous hemorrhage. 
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performance of PPV-BGI in 89 NVG eyes and found a
cumulative success rate of 67% in 73 eyes (82% of total) that
completed follow-up (6mo post-operatively), however, the
authors also considered eyes with LP visual acuity as
successes cases [27]. Fifty-five eyes (62% ) in the
aforementioned study presented improved or stable visual
acuity, a result that somewhat resembles ours, once 53% of
the NVG eyes in this series presented stable or improved
visual acuity and 8 (19% ) had light perception at 1-year
follow up visit. Also of note is that fifty-one eyes (58% of
total) in this recent case series received intravitreal
anti-VEGF injection perioperatively, in contrast to only 2
eyes (2%) in our study.
Progression of NVG implies increasing retinal ischemia and
increased production of vascular endothelial growth factor
(VEGF) [28,29]. The principal weakness of the current study is
that the interval during which these cases were studied
predated our more regular use of anti-VEGF therapy for eyes
undergoing combined PPV-BGI. Studies using off-label
intravitreal injection of bevacizumab (IVB) have reported
short-term efficacy and safety in NVG treatment, in
association with or not with other treatment modalities [30-35].
IVB has also been reported as an effective adjuvant for
surgical treatment of NVG [36-48]. Blocking anti-VEGF activity
to interrupt the vicious cycle of NVG aggravation is probably
helpful in improving the surgical outcome of NVG, but a
prospective randomized trial, or at least a larger, case-control
study specifically aiming to define the best setting (s) for its
surgical adjunctive use would likely be more definitive, but at
this point probably impractical. Any retrospective study is
subject to the biases of case ascertainment and individual
surgeon preferences; these were at least mitigated by this
being a consecutive case series, there being one vitreoretinal
surgeon (but several glaucoma surgeons), and little variation
in the retinal portion of the procedure.
Any surgical case series could have longer follow-up
examination intervals, but the nature of the tertiary practice
setting of the current study dictated these constraints; the
rapid declaration of clinical course in these sorts of cases
probably establishes the long term outcome early
post-operatively.
The current study, although retrospective and
non-randomized, shows encouraging results with the
performance of PPV-BGI (especially for non-NVG eyes),
offering the glaucoma specialist a viable option in selected
cases of refractory glaucoma. The best suited eyes for pars
plana insertion of the GDD are those with narrow or flat
angles, corneal decompensation, or those with florid rubeosis
iridis. The apparently disappointing results with NVG in our
series suggest the need to optimize the treatment approach for
those eyes, possibly through earlier PPV-BGI intervention
and/or use of anti-VEGF agents.
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